Metformin reduced the risk of heart failure and mortality in cancer patients receiving vascular endothelial growth factor inhibitor therapy, according to a retrospective cohort study presented at the American Heart Association Scientific Sessions in Chicago in November 2026.
Researchers evaluated a low-cost diabetes medication as a potential tool to protect the heart during specific oncology treatments.
"It’s a low-cost medication. It’s not associated with many side effects. So it’s an opportunity to add it to our toolbox," Haroun said. He acknowledged the limits of the composite end point, noting that standardized echocardiographic surveillance would likely be more reliable, but the database lacked the granularity to support it.
Haroun pointed to in vitro and preclinical data suggesting a mechanistic rationale for metformin’s cardioprotection. VEGF inhibitors lower endothelial nitric oxide bioavailability and provoke endothelial dysfunction via on-target impacts on the VEGF receptor. Metformin activates endothelial nitric oxide synthase and increases nitric oxide production, acting as a near-direct antagonism of this mechanism.
A similar parallel exists outside the endothelium. VEGF inhibitors exert off-target inhibition of AMP-activated protein kinase, a cellular energy regulator that can disrupt energy homeostasis. Metformin operates as a known AMPK activator to counter this disruption.
It remains unclear whether these mechanisms extend to broader cardiovascular protection. The analysis specifically examined left ventricular systolic dysfunction, cardiomyopathy, and heart failure. The research team has not studied hypertension or other VEGFi-related toxicities, which Haroun identified as targets for future research.
In the matched cohorts, metformin use was associated with lower all-cause mortality at 19.8% compared to 23.0% with a hazard ratio of 0.83, and new-onset metastatic cancer at 10.6% compared to 12.8% with a hazard ratio of 0.81. However, several prospective trials of metformin for oncologic outcomes have yielded disappointing results.
When researchers restricted an updated analysis solely to individuals diagnosed with type 2 diabetes, the signals for mortality and metastatic disease vanished. The association between metformin and the heart failure composite remained present in this population.
| Metric | Metformin Group | Control Group | Statistical Measure |
|---|---|---|---|
| All-Cause Mortality | 19.8% | 23.0% | HR, 0.83 (95% CI, 0.79–0.87; P < .001) |
| New-Onset Metastatic Cancer | 10.6% | 12.8% | HR, 0.81 (95% CI, 0.74–0.88; P < .001) |
No randomized trials have tested metformin for cardioprotection in cardio-oncology. Haroun favors a randomized trial comparing metformin with other diabetes therapies in patients with type 2 diabetes.
The study was presented at the American Heart Association Scientific Sessions, the flagship gathering of an organization founded in 1924 by six cardiologists in Chicago as the Association for the Prevention and Relief of Heart Disease.
A pivotal moment arrived in 1949 when a nationwide radio contest, The Walking Man, raised $1.5 million and transformed the group into a major research funder. Since then, the AHA has invested over $6.1 billion in cardiovascular, cerebrovascular, and brain health research and now mobilizes more than 33 million volunteers.
“I’m a little cautious about using metformin in patients who do not have diabetes or do not have an indication for metformin,” Haroun said.
He referenced the findings of the Diabetes Prevention Program, which appeared in the New England Journal of Medicine and demonstrated that metformin was most effective at preventing type 2 diabetes among younger individuals, participants with a BMI greater than 35, and those presenting with a high hemoglobin A1c.
Worth a look